labetalol + hydralazine + enalapril

This is a combination therapy consisting of three antihypertensive agents—labetalol, hydralazine, and enalapril—used together for the management of severe or resistant hypertension. - **Labetalol** is a non-selective beta-adrenergic blocker with selective alpha-1 adrenergic blocking activity, leading to decreased blood pressure through vasodilation and reduced heart rate[4][6]. - **Hydralazine** is a direct vasodilator that acts primarily on arterioles to decrease peripheral resistance and lower blood pressure[5][6]. - **Enalapril** is an angiotensin-converting enzyme (ACE) inhibitor that reduces the formation of angiotensin II, resulting in vasodilation and decreased aldosterone secretion[1][2]. The combination targets multiple mechanisms involved in hypertension control. Clinical experience suggests this regimen can be effective for patients with severe essential or renovascular hypertension who require multi-drug therapy for adequate blood pressure control[1][6]. This approach may be used when monotherapy or dual therapy does not achieve target blood pressures.